Akeso Biomedical is a food safety company focused on developing new solutions for the prevention of foodborne illnesses using a proprietary broad-spectrum iron complex chemistry (“Fe3C”) discovered by researchers at the University of Nottingham, UK. The Company’s product pipeline includes antibiotic-free feed additives designed to reduce the infection of poultry and other animals by Campylobacter, Salmonella, and E. coli.

Consultant to the medical device and biotech industry with specific expertise in: product development, absorbable polymers, implant devices, identification of new product opportunities for absorbable biomaterials, product development, development of intellectual property portfolios, and identification of strategic corporate partners and customers.

Tepha is a medical device company that develops and manufactures medical devices from a new class of proprietary absorbable biomaterials. Created the vision for Tepha, and pioneered its development beginning with the spinout of Tepha from Metabolix, and formulated a product development strategy that led to the FDA regulatory clearance of 17 novel medical device products over 5 years. Established strategic corporate partnerships that resulted in the commercial launch of Phasix™ hernia repair mesh with CR Bard, MonoMax® absorbable sutures with B. Braun Surgical, and BioFiber® Scaffold and Phantom Fiber™ for ligament and tendon repair with Tornier (acquired by Wright Medical and subsequently by Stryker Corporation). Acquired Galatea from The Vertical Group to form Tepha’s plastic surgery business, Galatea Surgical, and developed the GalaFLEX® Scaffold. Developed an intellectual property portfolio comprising 44 US patents, and entered into evaluation agreements with over 100 medical companies, hospitals, and institutions to develop collaborations in wound closure, hernia repair, orthopedic fixation, drug delivery, PFO closure, tissue engineering, hemostats, embolization, ligament and tendon repair, stents, plastic and reconstructive surgery, and ENT applications. Tepha was acquired by Becton Dickinson in 2021.

Co-founded Metabolix with Dr. Oliver Peoples and Professor Anthony Sinksey in 1992 as a spinout from the Massachusetts Institute of Technology. Metabolix was a leader in the development of bioplastics for industrial applications using genetic engineering, and marketed several brands of environmentally friendly biodegradable plastic. Developed the vision and initial business plan for Metabolix with senior management. Identified and developed potential applications for Metabolix's technology with specific responsibility for Metabolix's chemistry programs and specialty products, including the medical applications which were spun-off to Tepha and later acquired by Becton Dickinson. Metabolix raised $95 million with an IPO in 2007. Metabolix's biodegradable plastic business was sold to CJ Cheil Jedang in 2016. Metabolix now trades as Yield10.

Postdoctoral studies in Synthetic Organic Chemistry and Biological Chemistry with Professor Satoru Masamune and Professor Anthony Sinskey

Academic appointment in the Department of Organic Chemistry